Press Releases

PRESS RELEASE For immediate release Devonian Health Group Announces Hybrid Shareholders’ Annual General and Special Meeting QUEBEC, February 22nd, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP ANNOUNCES ITS PARTICIPATION AT BIO CEO & INVESTOR CONFERENCE QUEBEC, January 26, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP ANNOUNCES EXECUTIVE CHANGE AND GRANT OF STOCK OPTIONS   QUEBEC, January 6, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP INC. TO PARTICIPATE IN THREE RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES.   QUEBEC, October 24, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical...

PRESS RELEASE For immediate release DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES.   QUEBEC, October 12, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)...

PRESS RELEASE For immediate release Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology.   Clinical Study demonstrated dual benefit mode of action of Thykamine™ in...

PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS . QUEBEC, September 7, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage...

PRESS RELEASE For immediate release DEVONIAN ANNOUNCES EXECUTIVE CHANGES, GRANT OF STOCK OPTIONS AND SETTLEMENT OF INTERESTS AND REPAYMENT OF PRINCIPAL AMOUNT OWED TO A DEBENTURE HOLDER. Executive changes announced in support of the Corporation Growth Phase: Ms. Sybil...

PRESS RELEASE For immediate release Devonian Health Group Announces the Journal of Drugs in Dermatology acceptance for publication of Thykamine™ positive phase 2 clinical trial results in Atopic Dermatitis.   QUEBEC, May 26, 2022 – Devonian Health Group Inc....

PRESS RELEASE For immediate release Devonian Announces Adoption of Restricted Share Unit Plan.   QUEBEC, March 17th, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD ; OTCQB : DVHGF), a clinical stage botanical pharmaceutical...